First Episealer® surgery planned in Italy

Report this content

Episurf Medical (Nasdaq: EPIS B) today announces that the first surgery in Italy has been scheduled. Episurf Medical is currently working closely with its distributor in Italy, 4Medicals SRL, on marketing activities for the knee implant Episealer® Knee and ankle implant Episealer® Talus. The Episealer® Knee was registered and approved for sale and distribution in Italy during the fall of 2019 and the Episealer® Talus was registered and approved for sale and distribution in Italy in 2020.

“During January and February 2020, we sold more Episealer® implants than we ever have done during a full quarter before. Although the growth is driven by increased usage among existing customers, which is natural early on in our commercialization, we very much appreciate adding new countries. We are really happy that the first surgery has been scheduled in Italy” says Pål Ryfors, CEO Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: